EcoDrugPlus

Integrin Subunit Beta 1

Ensembl ID : ENSETEG00000000930
Gene Symbol: ITGB1
1 External references
301 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 3

Ensembl ID : ENSETEG00000001328
Gene Symbol: ITGB3
3 External references
131 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 5

Ensembl ID : ENSETEG00000003886
Gene Symbol: ITGB5
1 External references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 8

Ensembl ID : ENSETEG00000008606
Gene Symbol: ITGB8
1 External references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSETEG00000010234
Gene Symbol: IRAK4
1 External references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interleukin 5

Ensembl ID : ENSETEG00000007039
Gene Symbol: IL5
3 External references
91 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interstitial Collagenase

Ensembl ID : ENSETEG00000016822
Gene Symbol: -
2 External references
347 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSETEG00000016494
Gene Symbol: IDH1
1 External references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSETEG00000009862
Gene Symbol: IDH2
1 External references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kallikrein B1

Ensembl ID : ENSETEG00000008681
Gene Symbol: KLKB1
1 External references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinase Insert Domain Receptor

Ensembl ID : ENSETEG00000016586
Gene Symbol: KDR
1 External references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinesin Family Member 11

Ensembl ID : ENSETEG00000015319
Gene Symbol: KIF11
1 External references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).